Celesty
FDA Label NDC 81120-110
Full FDA labeling including Indications, Dosage, Usage, and Precautions
Structured Product Label
The following Structured Product Label (SPL) was submitted to the FDA by Maba Kozmetik Limited Sirketi for the product Celesty (NDC 81120-110). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding drug facts:, active ingredients, purpose, use, warnings, otc - keep out of reach of children, directions, other information, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
Label Section Quick Index
Active Ingredients
Homosalate: 8%
Avobenzone: 2,66%
Octocrylene: 6,98%
Octinoxate: 7,36%
Purpose
Sunscreen
Use
Helps prevent sunburn.
Warnings
For external use only.
Do not use on damaged or broken skin.
When using this product keep out eyes. Rinse with water to remove. Stop use and ask a doctor if rash occurs.
Otc - Keep Out Of Reach Of Children
Keep out of reach of children If swallowed, get medical help or contact a Poison Control Center right away.
Directions
• Apply minimum 30 minutes before sun exposure. • Repeat every 4 hours. • Reapply after swimming or sweating.
Other Information
Protect this product from excessive heat and direct sun. May stain some fabrics.
Inactive Ingredients
Water\Aqua\Eau, Cyclopentasiloxane, Butylene Glycol, Glyceryl Stearate, PEG-100 Stearate, Glycerin, Polysorbate 60, Polyhydroxystearic Acid, Allantoin, Dimethicone, Squalene, Bisabolol, Tocopheryl Acetate (Vitamin E), Stearic Acid, Propylene Glycol, Biosaccharide Gum-1, Triethanolamine, Panthenol (Pro Vitamin B5), Phenoxyethanol, Carbomer, Xanthan Gum, Sodium Benzoate, Potassium Sorbate, Aloe Barbadensis Leaf Juice, Peg-8, Tocopherol (Vitamin E), Ascorbyl Palmitate, Ascorbic Acid, Disodium EDTA, Camallia Sinensis Leaf Extract, BHT, Citric Acid.
Packaging
Image (811201103 1)
* Please review the disclaimer below.
